Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorder

scientific article published on 30 October 2018

Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorder is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1192/BJO.2018.56
P932PMC publication ID6235992
P698PubMed publication ID30450224

P50authorJun-ichi IgaQ48949274
Ryo OkuboQ86205160
P2093author name stringHiroto Ito
Norihiro Sato
Koichi Ito
Yasuhiro Matsuda
Minoru Honda
Ichiro Kusumi
Naoki Hashimoto
Yoichi M Ito
Keiichi Uemura
Jun Yamada
Yoshiteru Takekita
Nobuyuki Mitsui
Yuki Kako
Bunta Yoshimura
Yuki Arai
Akiko Konishi
Nobuyuki Nishi
Hiroyoshi Yamanaka
Kaoru Shinohara
Takayuki Segawa
Kiyoshi Tsuchiya
Akihiko Tochigi
Shinsaku Inomata
Noriko Tsukamoto
Yasufumi Sugawara
Yukihiko Matsuda
Ikuta Shinkawa
Sigehiro Matsubara
P2860cites workImpaired fasting glucose, blood pressure and cardiovascular disease mortalityQ44167916
Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods.Q50792652
Predictive value of prehypertension for metabolic syndrome, diabetes, and coronary heart disease among Turks.Q51118122
Progression from optimal blood glucose and pre-diabetes to type 2 diabetes in a high risk population with or without hypertension in Isfahan, Iran.Q51305749
Screening for diabetes using monitoring guidance in schizophrenia patients treated with second-generation antipsychotics: a 1-year follow-up study.Q51370027
Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.Q51557409
Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension,Q80584011
Consensus development conference on antipsychotic drugs and obesity and diabetesQ94355363
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesQ24608301
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisQ28303010
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1Q31145823
Screening for diabetes using Japanese monitoring guidance in schizophrenia patients treated with second-generation antipsychotics: a cross-sectional study using baseline dataQ33890480
Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countriesQ34796516
Diabetes and hypertension: is there a common metabolic pathway?Q35857205
Abnormalities of glucose metabolism associated with atypical antipsychotic drugsQ35985098
Metabolic monitoring for patients treated with antipsychotic medicationsQ36577861
Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjectsQ36744444
Postmortem analysis of cardiovascular deaths in schizophrenia: a 10-year reviewQ38136732
Sudden unexpected death in schizophrenia: autopsy findings in psychiatric inpatientsQ38202393
The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysisQ38460789
Prevalence and predictors of type 2 diabetes mellitus in people with bipolar disorder: a systematic review and meta-analysisQ38555006
Insulin resistance and hypertension in JapaneseQ41548287
Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: a nationwide retrospective cohort studyQ42653611
P275copyright licenseCreative Commons Attribution-NonCommercial-NoDerivs 4.0 InternationalQ24082749
P6216copyright statuscopyrightedQ50423863
P433issue6
P407language of work or nameEnglishQ1860
P921main subjectschizophreniaQ41112
bipolar disorderQ131755
hyperglycemiaQ271993
P304page(s)454-460
P577publication date2018-10-30
P1433published inBJPsych openQ27726839
P1476titlePredictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorder
P478volume4

Search more.